ACURATE Enhance Post Market Study

Inclusion Criteria: * Subject has documented severe aortic stenosis and an aortic annulus size compatible with the ACURATE neo2 valve per the commercial IFU based on the center's assessment of pre-procedure diagnostic imaging, and is deemed suitable for treatment with the ACURATE neo2™ Aortic Valve System (or future commercially available iteration) as confirmed by the Case Review Committee \[CRC\]. * Subject (or legal representative) understands the study requirements and provides written informed consent (eg, IEC-approved ICF). * Subject, family member, and/or legal representative agree(s) and subject is capable of returning to the study hospital for all study required follow-up visits. Exclusion Criteria: * Subject has a previously implanted bioprosthesis in the aortic position. * Subject has a unicuspid or bicuspid aortic valve. * Subject has either of the following: * Severe vascular disease that would preclude safe access (e.g., aneurysm with thrombus that cannot be crossed safely; marked tortuosity; significant narrowing of the abdominal aorta; severe unfolding of the thoracic aorta; or thick, protruding, ulcerated atheroma in the aortic arch), OR * Severe/eccentric calcification of the aortic annulus that would prevent safe implantation of the TAVI prosthesis. * Subject has known hypersensitivity to contrast agents that cannot be adequately pre-medicated or to the individual components of the study valve (nickel, titanium, processed porcine pericardium, polyet…